Therapeutic Approach

Archive: November, 2017

Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017

LOS ANGELES (November 29, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s president, Andrew Ritter, will present at the 10th Annual LD Micro Conference on Tuesday, December 5, 2017, at […]

Leave Your Comments »

Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress

LOS ANGELES (November 2, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, will present at the 5th Microbiome R&D Business Collaboration Forum / 2nd […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD